Loading...
Loading...
Browse all stories on DeepNewz
VisitFDA Approves J&J's RYBREVANT® and LAZCLUZE™ for EGFR-Mutated Lung Cancer
Aug 20, 2024, 11:18 AM
The U.S. Food and Drug Administration (FDA) has granted approval to Johnson & Johnson's chemotherapy-free combination therapy for treating a specific type of non-small cell lung cancer. The treatment, which includes RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib), is designed as a first-line option for patients with EGFR-mutated advanced lung cancer. This marks Johnson & Johnson's first FDA approval for a chemotherapy-free lung cancer treatment.
View original story
Markets
Yes • 50%
No • 50%
Stock market data from financial news sources and stock exchanges
Yes • 50%
No • 50%
FDA approval announcements and Johnson & Johnson press releases
No • 50%
Yes • 50%
Public announcements from major hospitals, healthcare publications, and Johnson & Johnson press releases
Below 20% • 25%
Above 60% • 25%
40% to 60% • 25%
20% to 40% • 25%
Market research reports and sales data from Johnson & Johnson
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
FDA approval announcements and press releases from pharmaceutical companies
European Union • 25%
Canada • 25%
Japan • 25%
Other • 25%
Approval announcements from respective country’s health regulatory agencies